Published in Eur J Med Res on November 03, 2009
Incidence of CMV co-infection in HIV-positive women and their neonates in a tertiary referral centre: a cohort study. Med Microbiol Immunol (2015) 0.80
HIV Prophylaxis in High Risk Newborns: An Examination of Sociodemographic Factors in an Inner City Context. Can J Infect Dis Med Microbiol (2016) 0.75
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1994) 25.02
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet (1999) 18.20
Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA (2000) 10.40
Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr (2002) 7.79
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med (2004) 6.48
The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies. The International Perinatal HIV Group. N Engl J Med (1999) 6.13
Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med (1998) 5.65
Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 5.17
Determinants of HIV-1 shedding in the genital tract of women. Lancet (2001) 5.10
Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med (1999) 5.05
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis (2003) 4.49
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1996) 4.44
Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet (1999) 4.20
A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med (2000) 4.14
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med (1999) 4.12
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis (2005) 3.59
Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS (2005) 3.52
Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med (2002) 3.31
Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis (2001) 2.95
Isolation of AIDS virus from cell-free breast milk of three healthy virus carriers. Lancet (1985) 2.77
Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA (2001) 2.63
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis (2005) 2.54
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS (2000) 2.49
Combination antiretroviral therapy and duration of pregnancy. AIDS (2000) 2.39
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA (2004) 2.31
Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS (2008) 2.19
Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS (2004) 2.10
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis (1998) 2.08
Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Engl J Med (1996) 2.08
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Recomm Rep (1998) 2.06
Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA (1998) 2.01
Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet (2002) 1.95
Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS (2003) 1.88
Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet (2004) 1.86
Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis (2000) 1.86
Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr (2003) 1.78
HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet (2002) 1.74
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS (2005) 1.73
Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr (2003) 1.68
Human immunodeficiency virus type 1-infected cells in breast milk: association with immunosuppression and vitamin A deficiency. J Infect Dis (1995) 1.62
Guidelines for the use of antiretroviral agents in pediatric HIV infection. Center for Disease Control and Prevention. MMWR Recomm Rep (1998) 1.60
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS (2003) 1.45
Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr (2003) 1.44
HIV-infected pregnant women and vertical transmission in Europe since 1986. European collaborative study. AIDS (2001) 1.40
Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol (2001) 1.39
Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis (1999) 1.38
Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis (2001) 1.38
Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. The European Collaborative Study. AIDS (1999) 1.38
Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.31
The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol (1993) 1.31
Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (2004) 1.28
Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Recomm Rep (1994) 1.28
Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol (2004) 1.26
Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis (1998) 1.23
Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis (2000) 1.23
Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr (2001) 1.21
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS (2003) 1.20
Exposure to HIV-1 during delivery and mother-to-child transmission. AIDS (2000) 1.18
Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group. J Infect Dis (1997) 1.17
Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J Acquir Immune Defic Syndr (2002) 1.17
Transplacental passage of protease inhibitors at delivery. AIDS (2002) 1.12
Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis (2003) 1.11
Higher rates of post-partum complications in HIV-infected than in uninfected women irrespective of mode of delivery. AIDS (2004) 1.10
Vertical transmission of HIV-1: maternal immune status and obstetric factors. The European Collaborative Study. AIDS (1996) 1.10
Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS (2003) 1.08
Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol (2002) 1.06
Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS (2002) 1.05
Pregnancy and HIV infection: A european consensus on management. AIDS (2002) 1.04
Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J (2002) 1.03
Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr (2003) 1.02
Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy. Eur J Clin Microbiol Infect Dis (2001) 1.01
Efavirenz reclassified as FDA pregnancy category D. AIDS Clin Care (2005) 1.01
Mode of delivery and postpartum morbidity among HIV-infected women: the women and infants transmission study. J Acquir Immune Defic Syndr (2001) 1.00
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS (2007) 0.99
Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol (2004) 0.98
Incorporation of 3'-azido-3'-deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. J Acquir Immune Defic Syndr (1999) 0.96
CD4+ lymphocytes in perinatal human immunodeficiency virus (HIV) infection: evidence for pregnancy-induced immune depression in uninfected and HIV-infected women. J Infect Dis (1995) 0.95
Complications according to mode of delivery among human immunodeficiency virus-infected women with CD4 lymphocyte counts of < or = 500/microL. Am J Obstet Gynecol (2000) 0.95
Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr (2003) 0.93
Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS (1999) 0.93
Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci U S A (2000) 0.93
Placental inflammation and perinatal transmission of HIV-1. J Acquir Immune Defic Syndr (2002) 0.92
Metabolism of 3'-azido-3'-deoxythymidine (AZT) in human placental trophoblasts and Hofbauer cells. Biochem Pharmacol (1994) 0.91
Immunological markers in HIV-infected pregnant women. The European Collaborative Study and the Swiss HIV Pregnancy Cohort. AIDS (1997) 0.90
Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis (1999) 0.90
Duration of ruptured membranes and extended labor are risk factors for HIV transmission. Int J Gynaecol Obstet (2003) 0.90
Postoperative morbidity associated with cesarean delivery among human immunodeficiency virus-seropositive women. Am J Obstet Gynecol (2001) 0.89
Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. Clin Infect Dis (2002) 0.89
Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr (2003) 0.89
German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res (2004) 0.89
HIV detection in amniotic fluid samples. Amniocentesis can be performed in HIV pregnant women? Eur J Obstet Gynecol Reprod Biol (2003) 0.88
Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4+ levels. J Acquir Immune Defic Syndr (1994) 0.86
PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat (2008) 0.86
Low complication rate associated with cesarean section under spinal anesthesia for HIV-1-infected women on antiretroviral therapy. Anesthesiology (2002) 0.86
Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. Ann Epidemiol (2009) 4.36
Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS (2010) 2.03
Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting. Eur J Epidemiol (2004) 1.50
Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis (2011) 1.49
Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther (2008) 1.21
Prevalence of pharyngeal and rectal Chlamydia trachomatis and Neisseria gonorrhoeae infections among men who have sex with men in Germany. Sex Transm Infect (2013) 1.19
Hidden from health: structural stigma, sexual orientation concealment, and HIV across 38 countries in the European MSM Internet Survey. AIDS (2015) 1.18
Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS (2010) 1.14
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol (2007) 1.09
Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer (2007) 1.06
Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer (2007) 1.04
Self-reported history of sexually transmissible infections (STIs) and STI-related utilization of the German health care system by men who have sex with men: data from a large convenience sample. BMC Infect Dis (2011) 1.01
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother (2006) 0.99
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol (2006) 0.99
Comparison of the performance of STI screening services for gay and bisexual men across 40 European cities: results from the European MSM Internet Survey. Sex Transm Infect (2013) 0.99
The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochem Cell Biol (2009) 0.98
Lymphogranuloma venereum in men screened for pharyngeal and rectal infection, Germany. Emerg Infect Dis (2013) 0.97
The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother (2008) 0.95
National Guidelines for the prevention of mother-to-child transmission of HIV across Europe - how do countries differ? Eur J Public Health (2013) 0.95
The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS (2013) 0.93
[Primary diagnosis of syphilis by the ophthalmologist]. Klin Monbl Augenheilkd (2002) 0.93
Low proportion of recent human immunodeficiency virus (HIV) infections among newly diagnosed cases of HIV infection as shown by the presence of HIV-specific antibodies of low avidity. J Clin Microbiol (2005) 0.90
Relationship between recurrent vulvovaginal candidosis and immune mediators in vaginal fluid. Eur J Obstet Gynecol Reprod Biol (2009) 0.87
Time trends of syphilis and HSV-2 co-infection among men who have sex with men in the German HIV-1 seroconverter cohort from 1996-2007. Sex Transm Infect (2010) 0.86
Pharmacokinetics, safety and transplacental passage of rilpivirine in pregnancy: two cases. AIDS (2014) 0.86
Diagnostic biomarkers of pro-inflammatory immune-mediated preterm birth. Arch Gynecol Obstet (2012) 0.86
Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol (2010) 0.85
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir Ther (2008) 0.85
High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women. Anticancer Res (2007) 0.85
Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease. Dis Colon Rectum (2014) 0.84
Cytomegalovirus genotypes present in cerebrospinal fluid of HIV-infected patients. AIDS (2005) 0.84
Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen. Antivir Ther (2007) 0.83
HIV coreceptor tropism in antiretroviral treatment-naive patients newly diagnosed at a late stage of HIV infection. AIDS (2010) 0.83
Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells. Biochem Biophys Res Commun (2008) 0.83
Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. Int J Radiat Oncol Biol Phys (2009) 0.83
Expression of the inhibin/activin subunits (-alpha, -betaA and -betaB) in normal and carcinogenic endometrial tissue: possible immunohistochemical differentiation markers. Oncol Rep (2007) 0.82
Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer (2009) 0.82
[Syphilis. Guideline of the German Sexually Transmitted Diseases Society fo diagnosis and therapy of syphilis]. J Dtsch Dermatol Ges (2006) 0.82
Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. Eur J Immunol (2012) 0.81
Influence of maternal age, gestational age and fetal gender on expression of immune mediators in amniotic fluid. BMC Res Notes (2012) 0.81
The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization. Mol Cancer (2010) 0.81
Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. Invest New Drugs (2009) 0.80
HIV testing in pregnancy: are we testing enough? Arch Gynecol Obstet (2010) 0.80
New prospects for nelfinavir in non-HIV-related diseases. Curr Mol Pharmacol (2010) 0.80
Evaluation of a temporary vaccination recommendation in response to an outbreak of invasive meningococcal serogroup C disease in men who have sex with men in Berlin, 2013-2014. Euro Surveill (2016) 0.80
Conversation about Serostatus decreases risk of acquiring HIV: results from a case control study comparing MSM with recent HIV infection and HIV negative controls. BMC Public Health (2014) 0.80
A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. Antivir Ther (2012) 0.79
HIV transmission despite HIV post-exposure prophylaxis after non-occupational exposure. AIDS (2004) 0.79
German-Austrian recommendations for HIV-therapy in pregnancy: update May 2003. Eur J Med Res (2004) 0.79
A multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven sampling. BMC Public Health (2014) 0.78
Safety of pharmacoenhancers for HIV therapy. Expert Rev Clin Pharmacol (2012) 0.78
The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells. Invest New Drugs (2011) 0.78
Immunohistochemical labeling of the inhibin/activin betaC subunit in normal human placental tissue and chorionic carcinoma cell lines. J Histochem Cytochem (2010) 0.76
Development and characterisation of an antibody for the immunohistochemical detection of inhibin/activin betaE (betaE) in normal human ovarian and placental tissue. Acta Histochem (2009) 0.76
Atazanavir exposure is effective during pregnancy regardless of tenofovir use. Antivir Ther (2014) 0.75
Increased incidence of syphilis in men who have sex with men and risk management strategies, Germany, 2015. Euro Surveill (2016) 0.75
Absence of human immunodeficiency virus infection after intentional injection of infected blood. Clin Infect Dis (2002) 0.75
The immunohistochemical expression of the inhibin/activin subunits is up-regulated by interferon-beta1a in Ishikawa cell line. Anticancer Res (2007) 0.75
Maternal HIV type 1 infection suppresses MMP-1 expression in endothelial cells of uninfected newborns: nonviral vertical transmission of HIV type 1-related effects. AIDS Res Hum Retroviruses (2005) 0.75
Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment. Ther Drug Monit (2014) 0.75
Anti-LGBT and Anti-Immigrant Structural Stigma: An Intersectional Analysis of Sexual Minority Men's HIV Risk When Migrating to or Within Europe. J Acquir Immune Defic Syndr (2017) 0.75
A systematic review of the use of atazanavir in women infected with HIV-1. Antivir Ther (2014) 0.75
[Pregnant with HIV infection: the risk for the child is minimal]. MMW Fortschr Med (2010) 0.75
Congenital cytomegalovirus infection in pregnancy: a case report of fetal death in a CMV-infected woman. Arch Gynecol Obstet (2007) 0.75
Serial knife stabbings with HIV exposure--implications for post-exposure prophylaxis. J Infect (2009) 0.75